To print: Select File and then Print from your browser's menu

Title: Enbrel (Etanercept) Provided Rapid, Significant Relief For Psoriasis Patients In Second Pivotal Study: Presented at IPS

"Enbrel (Etanercept) Provided Rapid, Significant Relief For Psoriasis Patients In Second Pivotal Study: Presented at IPS"

THOUSAND OAKS, CA and COLLEGEVILLE, PA -- June 23, 2003 -- Amgen (NASDAQ: AMGN), the world's largest biotechnology company, and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that patients in a second phase 3 clinical study assessing the efficacy and tolerability of Enbrel (etanercept) in the treatment of moderate to severe plaque psoriasis experienced significant and rapid improvement in their symptoms. The data were presented today at the International Psoriasis Symposium in New York City. In this global, double blind, placebo-controlled, multi-center study, 583 patients were randomized to receive 50 mg of ENBREL twice weekly (n=194), 25 mg of Enbrel twice weekly (n=196) or placebo (n=193). The primary endpoint of the study was the proportion of patients achieving a 75 percent or greater improvement in the Psoriasis Area and Severity Index (also known as PASI 75) after 12 weeks of treatment. Nearly half (49 percent) of the patients treated with 50 mg of ENBREL twice weekly and more than a third (34 percent) of patients treated with 25 mg of ENBREL twice weekly achieved a PASI 75 versus 3 percent of patients receiving placebo. "In this study, a significant number of patients experienced rapid improvement in as quickly as two weeks after receiving ENBREL," said primary investigator Dr. Kim Papp of Probity Medical Research in Waterloo, Canada. "In addition, physicians assessed their patients as having 'clear' or 'almost clear' skin in 57 percent of patients treated with ENBREL 50 mg twice weekly, and 39 percent treated with Enbrel 25 mg twice weekly, compared with 4 percent of placebo-treated patients." Patients were asked to assess the effect of Enbrel on their psoriasis and the impact that ENBREL treatment had on their lives as measured by the Dermatology Life Quality Index over the course of the study. Patients treated with ENBREL 50 mg twice weekly reported 71 percent improvement after 12 weeks and patients treated with Enbrel 25 mg twice weekly reported 66 percent improvement. Both treatment groups experienced improvement after just two weeks of treatment. "We have now studied Enbrel in two large and well-controlled studies of psoriasis patients," said Dr. Beth Seidenberg, Amgen's senior vice president of development. "We are encouraged by the replicated results and look forward to submitting an application to the U.S. Food and Drug Administration seeking approval for Enbrel in the treatment of a fifth inflammatory disease." Enbrel is currently under review for a fourth inflammatory disease, ankylosing spondylitis. The supplemental application will be the subject of a U.S. Food and Drug Arthritis Advisory committee meeting on June 24, 2003. Enbrel was generally well tolerated in the study. Adverse events were similar to those reported in previous clinical trials of Enbrel, with injection site reactions occurring more frequently than in the placebo group. The most frequent adverse events in placebo-controlled RA clinical trials (n=349) were injection site reactions (ISR) (37%), infections (35%), and headache (17%). Only the rate of ISR was higher than that of placebo. The most frequent adverse events in a methotrexate-controlled trial (n=415) were infections (64%), ISR (34%), and headache (24%). Only the rate of ISR was higher than that of methotrexate. Psoriasis is characterized by chronic inflammation of the skin. This inflammation drives the formation of red, itchy skin plaques that are painful and disfiguring. Tumor necrosis factor (TNF) is found at high levels in psoriatic plaques, and plays a critical role in their formation and maintenance. Psoriasis affects nearly 7 million people in the United States, one million of whom have moderate to severe plaque psoriasis. Enbrel is not approved by the U.S. Food and Drug Administration for the treatment of psoriasis. ABOUT ENBREL Enbrel is the only fully human anti-TNF receptor approved for use to reduce the signs and symptoms of active arthritis in patients with psoriatic arthritis, and to reduce the signs and symptoms and inhibit the structural damage in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel is the only biologic therapy approved to treat newly diagnosed RA patients, and can be used alone. It is also approved to reduce the signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis (JRA) in patients as young as four years of age who have had an inadequate response to disease-modifying medicines. Physicians have become familiar with the benefits and proven long-term tolerability profile of Enbrel. It has been used to treat over 180,000 patients worldwide since becoming commercially available four years ago. Enbrel acts by binding TNF, one of the dominant inflammatory cytokines or regulatory proteins that play an important role in both normal immune function and the cascade of reactions that causes the inflammatory process. The binding of Enbrel to TNF renders the bound TNF biologically inactive, resulting in significant reduction in inflammatory activity. Since the product was first introduced, the following have been reported in patients using Enbrel: o Serious Infections · Many occurred in people prone to infection, such as those with advanced or poorly controlled diabetes · Some serious infections were fatal · Rare cases of tuberculosis o What to do/Not do · Do not start Enbrel if you have an infection or are allergic to Enbrel or its components · Tell your doctor if you are prone to infection · Stop Enbrel if a serious infection occurs · Contact your doctor if you have questions about Enbrel or develop an infection o Serious nervous system disorders such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes. · Tell your doctor if you have ever had any of these disorders or if you develop them after starting Enbrel. o Rare reports of serious blood disorders (some fatal) · Contact your doctor immediately if you develop symptoms such as persistent fever, bruising, bleeding, or paleness o The incidence of cancer has not increased with extended exposure to Enbrel and is similar to the expected rate. o Enbrel can also cause injection site reactions. o In a medical study of patients with JRA, infections, headaches, abdominal pain, vomiting, and nausea occurred more frequently than in adults. · The kinds of infections reported were generally mild and similar to those usually seen in children · Other serious adverse reactions were reported rarely, including serious infections (2%) and depression/personality disorder (1%) with the inherent uncertainty of pharmaceutical research, product. SOURCE: Porter Novelli

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.